Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

647 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT02337530 2024-03-21

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

62 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT01783197 2023-08-04

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

39 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02503358 2023-03-21

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

23 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01146756 2023-02-15

MEKRT

21 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

334 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01586624 2021-10-07

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

61 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02025114 2018-07-10

Selumetinib in Combination With Gefitinib in NSCLC Patients

Phase 1/2 Completed

34 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00890825 2018-06-20

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

88 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT03004105 2018-03-16

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01229150 2017-05-23

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

89 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01605916 2016-10-21

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

33 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00372788 2014-08-13

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

88 enrolled